European Union approves AstraZeneca's Fasenra for EGPA, expanding its rare disease portfolio.

The European Union has approved AstraZeneca's Fasenra for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). This decision is a significant milestone for the company, enhancing its portfolio in targeted therapies for rare diseases.

October 28, 2024
4 Articles